linsitinib
Sign in to saveAlso known as OSI-9606
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- neoplasm, small cell lung carcinoma, hepatocellular carcinoma, prostate adenocarcinoma
via ChEMBL · EBI
Wikidata facts
- Mass
- 421.19026035599995
Show 4 more facts
- isomeric SMILES
- C[C@]1(C[C@@H](C1)C=2N3C(C(=NC=C3)N)=C(N2)C4=CC5=NC(=CC=C5C=C4)C6=CC=CC=C6)O
- canonical SMILES
- CC1(CC(C1)C=2N3C(C(=NC=C3)N)=C(N2)C4=CC5=NC(=CC=C5C=C4)C6=CC=CC=C6)O
- chemical formula
- C₂₆H₂₃N₅O
- Commons category
- Linsitinib
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.
Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012.
Excerpted from Wikipedia’s “linsitinib” article, available under the CC BY-SA 4.0 licence.